Stockscreener 앱 받기
3.7501
7.83%
-0.3184
전일 마감가:
$4.0685
열려 있는:
$4.0043
하루 거래량:
4,867
Relative Volume:
0.55
시가총액:
$192.87M
수익:
$27,600
순이익/손실:
$-36.04M
주가수익비율:
-2.1161
EPS:
-1.7722
순현금흐름:
$-1.66M
1주 성능:
-7.40%
1개월 성능:
-22.04%
6개월 성능:
-47.26%
1년 성능:
-37.50%
1일 변동 폭
$3.77
$4.0043
1주일 범위
$3.5733
$4.2036
52주 변동 폭
$3.5733
$8.962
나노바이오틱스 Stock (NBTX) Company Profile
NBTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| NBTX | 3.795 | 192.87M | 27,600 | -36.04M | -1.66M | -1.7722 |
| VRTX | 450.67 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 746.27 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.22 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.29 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.27 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
나노바이오틱스 Stock (NBTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-01-06 | 개시 | Evercore ISI | Outperform |
나노바이오틱스 주식(NBTX)의 최신 뉴스
NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms - GlobeNewswire Inc.
Nanobiotix (NASDAQ:NBTX) Trading Down 14% - Defense World
Nanobiotix (NASDAQ:NBTX) Stock Price Down 14% - MarketBeat
Nanobiotix S.A. (NASDAQ:NBTX) Forecasted to Earn FY2025 Earnings of $0.88 Per Share - MarketBeat
Earnings call: Nanobiotix reports Q1 2024 results, advances with NBTXR3 By Investing.com - Investing.com
NANOBIOTIX Co-Founder and CEO Laurent Levy Named to 2022 PharmaVoice 100 List of Most Inspiring People in ... - The Globe and Mail
Nanobiotix Announces Latest Share and Voting Rights UpdateTipRanks.com - TipRanks
Nanobiotix Prepares to Unveil Q1 2024 ResultsTipRanks.com - TipRanks
Nanobiotix's NBTXR3 Enters Phase 2 Lung Cancer StudyTipRanks.com - TipRanks
Nanobiotix's Revenue at Risk: The High Stakes of Sole Dependence on Janssen PartnershipTipRanks.com - TipRanks
Nanobiotix Sa ADR Updates Share Capital InfoTipRanks.com - TipRanks
Nanobiotix Advances NBTXR3 for Lung Cancer TreatmentTipRanks.com - TipRanks
NANOBIOTIX Annual Shareholders’ General Meeting to Be Held on June 23, 2022 - The Globe and Mail
NANOBIOTIX Announces 18.1 Month Median Overall Survival for 41 Evaluable Elderly and Frail Patients With HNSCC ... - The Globe and Mail
NANOBIOTIX Reports New Data for Potential First-in-Class Radioenhancer NBTXR3 in Combination With Anti-PD-1 Showing Local or Distant Tumor Regression in 76.9% of Evaluable Patients Regardless of Prior Anti-PD-1 Exposure - Business Wire
NANOBIOTIX Announces the Appointment of Bart Van Rhijn as Chief Financial Officer and Member of the Executive ... - The Globe and Mail
NANOBIOTIX Partners With LianBio to Develop and Commercialize Potential First-in-Class Radioenhancer NBTXR3 Across Tumor Types and Therapeutic Combinations in China and Other Asian Markets - Business Wire
IPO Launch: Nanobiotix S.A. Pursues $96 Million IPOIPOs On TheStreetU.S. IPO Research & Opinion - TheStreet
NBTX News Today | Why did Nanobiotix stock go down today? - MarketBeat
Nanobiotix (NBTX) Stock Price, News & Analysis - MarketBeat
Nanobiotix - Massachusetts Biotechnology Council
나노바이오틱스 (NBTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.80%
0.42%
자본화:
|
볼륨(24시간):